Japan's Teijin Pharma is abandoning its licensing-development course and turning to more direct involvement in developing and selling drugs in Asia. The company has been marketing drugs in China since 2006, but now plans clinical trials in China and Thailand for a new gout drug it plans to market throughout Asia. The drug TMX-67 (febuxostat) has been licensed to a South Korean firm for marketing in that country, but Teijin plans to develop and market the drug by itself in the rest of Asia, where it expects the drug to become a best-seller. Teijin also makes and markets medical equipment. (Click here for more - a subscription may be required
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
